Oramed continues trials for oral insulin capsule

JERUSALEM Oramed Pharmaceuticals has begun Phase 1B clinical trials for its oral insulin capsule to treat diabetes.

The trials are set up to find the proper dosage for the company’s drug delivering technology. This is a continuation of successfully completed Phase 1A trials.

“Oramed is excited to move forward with our lead drug candidate,” commented Nadav Kidron, chief executive officer of Oramed. “This phase of the trial, following the successful completion of our Phase 1A trials, is a significant milestone for Oramed and for our oral insulin product. We are pleased to be one step closer to our goal of offering the many diabetes patients around the world a viable oral insulin solution.”

The company plans to its Phase 1 studies by the third quarter of 2008.